PharmaCyte Biotech (PMCB) Preferred Dividend Payments (2013 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Preferred Dividend Payments of $396569.0 for Q2 2026, down 97.94% year-over-year from $19.3 million in Q2 2025, and down 82.01% quarter-over-quarter from $2.2 million in Q1 2026.
PharmaCyte Biotech (PMCB) Preferred Dividend Payments (2013 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Preferred Dividend Payments for 5 consecutive years, with $396569.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Preferred Dividend Payments fell 97.94% year-over-year to $396569.0; the TTM figure through Apr 2026 stood at $3.5 million (down 84.42% YoY), while the FY2026 annual figure was $3.5 million, down 84.42% from the prior year.
- Preferred Dividend Payments slipped to $396569.0 in Q2 2026 per PMCB's latest filing, from $2.2 million in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $19.3 million in Q2 2025 and bottomed at $396569.0 in Q2 2026.
- Historically, Preferred Dividend Payments has averaged $4.2 million across 4 years, with a median of $2.7 million in 2023.
- Annual changes were most pronounced in 2025 — Preferred Dividend Payments surged 363.25% — and 2026, when it slumped 97.94%.
- PharmaCyte Biotech's Preferred Dividend Payments stood at $4.5 million in 2023, then slumped by 76.57% to $1.0 million in 2024, then decreased by 13.71% to $901996.0 in 2025, then sank by 56.03% to $396569.0 in 2026.
- Business Quant data shows PMCB's Preferred Dividend Payments at $396569.0 in Q2 2026, $2.2 million in Q1 2026, and $901996.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - | 396,569.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 396,569.00 |
| Jan 31, 2026 | 2.20 Mn |
| Oct 31, 2025 | 901,996.00 |
| Apr 30, 2025 | 19.29 Mn |
| Oct 31, 2024 | 1.05 Mn |
| Jul 31, 2024 | 2.15 Mn |
| Apr 30, 2024 | 4.16 Mn |
| Jan 31, 2024 | 4.22 Mn |
| Oct 31, 2023 | 4.46 Mn |
| Jul 31, 2023 | 3.27 Mn |
| Jul 31, 2013 | 640,000.00 |